

# Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

*Information and documents given to ASX become ASX's property and may be made public.*

Name of entity

Sigma Pharmaceuticals Limited

ABN/ARSN

15 088 417 403

We (the entity) give ASX the following information.

### Information about buy-back

|   |                                   |  |
|---|-----------------------------------|--|
| 1 | Type of buy-back                  | On-market buy-back   |
| 2 | Date Appendix 3C was given to ASX | 13 September 2012<br>(Associated Appendix 3D dated 18 November 2015) |

### Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

|   | Before previous day  | Previous day             |
|---|--|--------------------------|
| 3 | Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received | 110,921,420<br>100,000   |
| 4 | Total consideration paid or payable for the shares/units   | \$80,792,687<br>\$83,600 |

**Appendix 3E**  
**Daily share buy-back notice**

---

|   |                                      | Before previous day   | Previous day  |
|---|--------------------------------------|---|---|
| 5 | If buy-back is an on-market buy-back | Highest price paid:<br>\$0.8700<br><br>Lowest price paid:<br>\$0.5600 | Highest price paid:<br>\$0.8450<br><br>Lowest price paid:<br>\$0.8225<br><br>Highest price allowed under rule 7.33:<br>\$0.8959 |

**How many shares/units may still be bought back?**

|   |   |           |
|---|---|-----------|
| 6 | If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back | 7,608,932 |
|---|---|-----------|

**Compliance statement**

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

*or, for trusts only:*

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here:

(Director/Company secretary)

Date: 3 December 2015

Print name:

JEFF SELLS

== == == == ==

---